EUROIMMUN Medizinische Labordiagnostika AG was founded in 1987 by the University of Lübeck (Germany). In 2018, the American company PerkinElmer, Inc. became the sole shareholder of Euroimmun. In 2023, the two PerkinElmer business divisions “Life Sciences” and “Diagnostics” were converted into the new company Revvity, Inc., which also includes Euroimmun. As one of the leading manufacturers of medical laboratory diagnostics worldwide, Euroimmun stands for innovation. More than 3400 employees in 17 countries develop, produce, and sell test systems to support the diagnosis of diseases, as well as software and automation solutions for the performance and evaluation of these tests. Laboratories in over 140 countries utilize Euroimmun products for the diagnosis of autoimmune and infectious diseases, as well as allergies, and for performing genetic analyses. Euroimmun US was established in 2012 to meet the needs of North America.
Euroimmun US, headquartered in New Jersey, provides specialized diagnostic solutions and dedicated support for the US and Canadian markets. We focus on delivering high-quality autoimmune, infectious disease, allergy, and hormone testing systems that meet the specific needs of North American laboratories. Our team collaborates closely with clinical laboratories, hospitals, and research institutions, offering not only diagnostic products but also comprehensive automation platforms, training resources, and scientific expertise tailored for local workflows and regulatory requirements.
As part of Revvity, Euroimmun US benefits from the strength of a global organization driving innovation in healthcare, life sciences, and diagnostics. Together, we deliver integrated solutions that empower laboratories to improve patient care and advance scientific discovery.
Stay in the know about new product releases, events and more!
2025 Euroimmun US
Privacy Policy | Website Terms and Conditions | Cookie Notice and Settings | Consent Preferences | Sitemap